Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Blood

Volumn 119, Issue 19, 2012, Pages 4391-4394

  Mikhael, Joseph R ^a   Schuster, Steven R ^a   Jimenez Zepeda, Victor H ^b   Bello, Nancy ^a   Spong, Jacy ^a   Reeder, Craig B ^a   Stewart, A Keith ^a   Bergsagel, P Leif ^a   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE;

AMYLOIDOSIS; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; DRUG TOLERANCE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY DISEASE; LIGHT CHAIN AMYLOIDOSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE;

EID: 84860898706     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-390930     Document Type: Article

References (22)

1. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(2):180-186.
2. Skinner M. AL amyloidosis: the last 30 years. Amyloid. 2000;7(1):13-14. (Pubitemid 30317620)
3. Dispenzieri A, Gertz MA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. (Pubitemid 41095215)
4. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-18.
5. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med. 1997;336(17):1202-1207. (Pubitemid 27183649)
6. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938. (Pubitemid 38451663)
7. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561-3563. (Pubitemid 350159622)
8. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093. (Pubitemid 47443213)
9. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51(12):2181-2187.
10. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257-261. (Pubitemid 38117510)
11. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470. (Pubitemid 46105939)
12. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496. (Pubitemid 46105943)
13. Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010;116(1):1990-1991.
14. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood. 2010;116(23):4777-4782.
15. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2011;91(1):89-92.
16. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
17. Reeder CB, Reece DE, Kukreti V, et al. Onceversus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-3417.
18. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-4959.
19. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France 18-22 April 2004. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)
20. Gertz MA, Lacy MQ, Dispenzieri AD, et al. Transplantation for immunoglobulin light chain amyloidosis: a statistical analysis of factors predicting outcome in over 400 patients [abstract]. Blood. 2010;116:Abstract 3557.
21. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90(2):201-206.
22. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92:1351-1358. (Pubitemid 350144152)